Chen Wan-Jin, Wu Zhi-Ying, Lin Min-Ting, Su Jun-Feng, Lin Yu, Murong Shen-Xing, Wang Ning
Department of Neurology and Institute of Neurology, First Affiliated Hospital, Fujian Medical University, 20 Chazhong Road, Fuzhou 350 005, China.
Arch Neurol. 2007 Feb;64(2):225-31. doi: 10.1001/archneur.64.2.225.
The difficulties and incurability of spinal muscular atrophy (SMA) highlight the importance of prenatal diagnosis in families with SMA. However, the system applied in prenatal screening is far from perfect.
To optimize the molecular assays and establish a relatively perfect system for prenatal screening. Design, Setting, and Patients A total of 87 patients and 132 parents from 77 families with SMA were screened for SMN1 mutations. Prenatal prediction was performed for 11 fetuses from 10 families with SMA. All of the samples to be tested were from the Department of Neurology, First Affiliated Hospital, Fujian Medical University, Fuzhou, China.
All of the 87 patients and their parents were screened for SMN1 deletion by restriction fragment length polymorphism analysis and denaturing high-performance liquid chromatography (DHPLC). For those patients without the SMN1 deletion, the SMN1 copy numbers were detected by real-time fluorescence quantitative polymerase chain reaction and the subtle mutations of SMN were screened by direct sequencing. Prenatal prediction was performed by restriction fragment length polymorphism analysis, DHPLC, and linkage analysis for 11 fetuses. Furthermore, the SMN1 copy numbers and detected carriers of SMA were found by DHPLC and real-time fluorescence quantitative polymerase chain reaction in 14 parents and the fetuses without the SMN1 deletion. Results in aborted fetuses and born babies were reconfirmed by restriction fragment length polymorphism analysis and DHPLC. The born babies were followed up and physically examined twice a year.
The frequency of the SMN1 deletion we detected was 93.5% (72 of 77 patients). No subtle mutations were detected in the other 5 families. Four fetuses had the SMN1 deletion and were aborted. The other 7 fetuses, 4 carriers and 3 normal individuals, were born under suggestion by the physician. Fourteen parents were carriers. The reconfirmation of results in the aborted fetuses and born babies was completely consistent with prenatal prediction. The 7 born babies were followed up until recently and all were normal.
The molecular diagnosis system based on restriction fragment length polymorphism analysis, DHPLC, and linkage analysis is an efficient and accurate method that is well suited for routine use in clinical laboratories.
脊髓性肌萎缩症(SMA)的难治性和不可治愈性凸显了在SMA家庭中进行产前诊断的重要性。然而,目前应用于产前筛查的系统远非完美。
优化分子检测方法,建立相对完善的产前筛查系统。设计、场所和患者 对来自77个SMA家庭的87例患者及132名父母进行SMN1突变筛查。对10个SMA家庭的11例胎儿进行产前预测。所有待检测样本均来自中国福州福建医科大学附属第一医院神经内科。
采用限制性片段长度多态性分析和变性高效液相色谱法(DHPLC)对87例患者及其父母进行SMN1缺失筛查。对于无SMN1缺失的患者,采用实时荧光定量聚合酶链反应检测SMN1拷贝数,并通过直接测序筛查SMN的微小突变。对11例胎儿采用限制性片段长度多态性分析、DHPLC和连锁分析进行产前预测。此外,对14名父母及无SMN1缺失的胎儿,采用DHPLC和实时荧光定量聚合酶链反应检测SMN1拷贝数并发现SMA携带者。对引产胎儿和出生婴儿的结果采用限制性片段长度多态性分析和DHPLC进行再次确认。对出生婴儿进行随访,每年进行两次体格检查。
检测到的SMN1缺失频率为93.5%(77例患者中的72例)。其他5个家庭未检测到微小突变。4例胎儿存在SMN1缺失并引产。其他7例胎儿,4例携带者和3例正常个体,在医生建议下出生。14名父母为携带者。引产胎儿和出生婴儿结果的再次确认与产前预测完全一致。7例出生婴儿随访至近期,均正常。
基于限制性片段长度多态性分析、DHPLC和连锁分析的分子诊断系统是一种高效、准确的方法,非常适合临床实验室常规使用。